News | November 01, 2024
AbbVie to acquire Aliada Therapeutics
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
Subscribe To Our Newsletter & Stay Updated
